Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of VX-548 in Healthy Adults
NCT05851157Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of suzetrigine in pain, sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 35, Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration at Day 35 and 1 more. Started May 2023; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05851157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851157.